Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook

Stock Track

Feb 28, 2025

Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.

The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.

For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:

Adding over 80 new clients, including its first national health plan partner, Cigna.
Expanding services offerings in areas like maternity, postpartum, and menopause.
Retaining 99% of existing clients, reflecting high satisfaction.
Continued investments in digital assets and product development.

While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197750619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197750619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197750619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 22:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197750619","market":"us","top_or_hot":-1,"title":"Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook","media":"Stock Track","content":"<p>Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.</p>\n\n<p>The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.</p>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:</p>\n\n<ul>\n<li>Adding over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanding services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retaining 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Progyny Soars 16% as Q4 Earnings Beat Propels Robust Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 22:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.</p>\n\n<p>The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.</p>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:</p>\n\n<ul>\n<li>Adding over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanding services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retaining 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGNY","symbol_name":"Progyny","start_time":0,"source_url":"","article_id":"1197750619","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197750619","pubTimestamp":1740753519,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Progyny  stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.The fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.For the full year 2024, Progyny's reve","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGNY":"Progyny"},"translate_title":"股票跟踪Progyny飙升16%，第四季度盈利超出预期推动强劲增长前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1},"content_text":"Progyny (PGNY) stock surged 16.04% in the pre-market session on Friday, driven by the company's impressive fourth-quarter 2024 earnings and optimistic guidance for continued growth.\nThe fertility benefits provider reported strong financial results for Q4 2024, with revenue increasing 11% year-over-year to $298.4 million, exceeding guidance. Adjusted EBITDA rose 10% to $47.5 million, and the company achieved a record quarterly ART cycle volume of over 15,800 cycles.\nFor the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's robust performance was fueled by several key factors:\n\nAdding over 80 new clients, including its first national health plan partner, Cigna.\nExpanding services offerings in areas like maternity, postpartum, and menopause.\nRetaining 99% of existing clients, reflecting high satisfaction.\nContinued investments in digital assets and product development.\n\nWhile Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}